Skip to main content
SCM Lifescience Co., Ltd. logo

SCM Lifescience Co., Ltd. — Investor Relations & Filings

Ticker · 298060 ISIN · KR7298060005 KO Manufacturing
Open in API
Filings indexed 418 across all filing types
Latest filing 2024-02-14 AGM Information
Country KR South Korea
Listing KO 298060

About SCM Lifescience Co., Ltd.

http://www.scmlifescience.com/en/

SCM Lifescience Co., Ltd. is a biotechnology company focused on developing high-purity, high-efficacy stem cell therapeutics for difficult-to-treat and incurable diseases. The company utilizes its proprietary source technology, the Subfractionation Culturing Method, to isolate and culture potent stem cells. Its pipeline consists of allogeneic stem cell therapies targeting immunological conditions, which are undergoing clinical trials. SCM Lifescience is also establishing mass production manufacturing processes using 3D bioreactor technology and expanding its research into induced pluripotent stem cells (iPSC) and tissue engineering. The company's business areas also include contract manufacturing (CMO), contract research, consulting, and cosmetics.

Recent filings

Filing Released Lang Actions
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by SCM Life Science. It outlines the date, location, and agenda items (such as approval of financial statements and director compensation) for the upcoming Annual General Meeting. This type of document is a standard proxy solicitation or notice of meeting, which falls under the Proxy Solicitation & Information Statement category.
2024-02-14 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically functions as a '정정신고' (Correction Report) regarding previously granted stock options. It details changes to the number of shares and the list of recipients due to employee resignation. In the context of financial filings, reports regarding stock option grants, amendments, or cancellations are classified under 'Regulatory Filings' (RNS) as they represent specific corporate disclosures to regulatory bodies that do not fall into the other specialized categories like Director's Dealing or Share Issue.
2024-02-14 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from SCM Lifescience regarding a significant change (over 30%) in revenue or profit structure. This is a standard disclosure requirement in South Korean financial markets (DART system) for companies to report material changes in financial performance before the final audit is completed. It provides key financial highlights and reasons for the change, fitting the definition of an Earnings Release (ER) as it is an initial announcement of financial results/highlights. FY 2023
2024-02-02 Korean
[기재정정]신규시설투자등
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from SCM Lifescience regarding a 'Correction Report' (정정신고) for a 'New Facility Investment' (신규시설투자). It details changes to investment amounts and timelines due to external economic factors. Since this is a specific regulatory disclosure regarding capital expenditure and investment updates that does not fit into categories like M&A, dividends, or earnings, it is classified as a general Regulatory Filing (RNS).
2023-12-22 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date for a shareholder meeting (Annual General Meeting). It is not the meeting materials themselves, but a notice of the record date for the upcoming meeting. Given the nature of the announcement as a regulatory disclosure regarding corporate governance and shareholder rights, it fits best under the RNS (Regulatory Filings) category as it is a standard corporate notice.
2023-12-22 Korean
분기보고서 (2023.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for SCM Lifescience, Inc. (에스씨엠생명과학 주식회사) covering the period from January 1, 2023, to September 30, 2023. It contains detailed financial information, business operations, management discussions, and capital structure updates, which are characteristic of a formal quarterly financial filing. According to the provided definitions, this falls under the 'Interim / Quarterly Report' (IR) category. 9M 2023
2023-11-14 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.